Search results for "ALAT"

showing 10 items of 4241 documents

The Use of Hall's Technique Preformed Metal Crown (HTPMC) by Pediatric Dentists in Malaysia

2021

Introduction. Hall’s technique preformed metal crown (HTPMC) has been used widely by pediatric dentists in developed countries as a new approach for managing decayed primary molars without local anesthesia, caries removal, and tooth preparation. Currently, inadequate information is available regarding the implementation of this technique (HTPMC) in Malaysia. This study is aimed at evaluating the implementation of HTPMC by Malaysia’s pediatric dentists and identify the co-occurrence frequencies of the HTPMC implementation with the respondents’ demographic profile. Materials and Methods. A cross-sectional questionnaire-based research was conducted among 65 pediatric dentists in Malaysia. Onli…

AdultMaleArticle SubjectDentistsDental CariesGeneral Biochemistry Genetics and Molecular BiologySettore MED/28 - Malattie OdontostomatologicheSurveys and QuestionnairesHumansTooth DeciduousDental Restoration PermanentPractice Patterns Dentists'preformed metal crownGeneral Immunology and MicrobiologyCrownsRMalaysiaGeneral MedicineMiddle AgedMolarCross-Sectional StudiesMedicineFemaleDental Cavity PreparationHall’s TechniqueResearch ArticleBioMed Research International
researchProduct

Driving habits and risk factors for traffic accidents among sleep apnea patients - a European multi-centre cohort study

2014

Obstructive sleep apnea is associated with increased motor vehicle accident risk, and improved detection of patients at risk is of importance. The present study addresses potential risk factors in the European Sleep Apnea Database and includes patients with suspected obstructive sleep apnea [n = 8476, age 51.5 (12.5) years, body mass index 31.0 (6.6) kg m(-2) , 82.4% driver's licence holders]. Driving distance (km year(-1) ), driver's licence type, sleep apnea severity, sleepiness and comorbidities were assessed. Previously validated risk factors for accident history: Epworth Sleepiness Scale ≥16; habitual sleep time ≤5 h; use of hypnotics; and driving ≥15 000 km year(-1) were analysed acro…

AdultMaleAutomobile DrivingPediatricsmedicine.medical_specialtyAdolescentDatabases FactualCognitive NeurosciencePoison controlSettore MED/10 - Malattie Dell'Apparato RespiratorioCohort StudiesYoung AdultBehavioral NeuroscienceRisk FactorsPrevalencedriving exposure hypersomnia motor vehicle crash registry sleepy driving traffic riskHumansMedicineAttentionRisk factorAgedAged 80 and overSleep Apnea Obstructivebusiness.industryEpworth Sleepiness ScaleAccidents TrafficSleep apneaApneaGeneral MedicineMiddle Agedmedicine.diseaseObesityEuropeObstructive sleep apneaFemaleMedical emergencymedicine.symptomSleepbusinessCohort studyJournal of Sleep Research
researchProduct

Asymptomatic Leishmania infantum/chagasi infection in blood donors of western Sicily.

2007

The purpose of this study was to evaluate whether the risk of transfusion-transmitted visceral leishmaniasis was present in an area of western Sicily where the incidence of the disease is higher than the regional average. From May to December 2005, 1449 blood donors from Agrigento district (Sicily, Italy) were screened for the presence of anti-Leishmania antibodies by an indirect immunofluorescent antibody test (IFAT). Blood samples from IFAT-positive donors were examined by PCR to detect Leishmania DNA. Anti-Leishmania antibodies were found in 11 (0.75%) cases, among which Leishmania DNA was detected from four (36.4%). Particular techniques to inactivate different pathogens would be consid…

AdultMaleBlood transfusionSettore MED/17 - Malattie Infettivemedicine.medical_treatmentAntibodies ProtozoanBlood DonorsParasitemiaSettore MED/42 - Igiene Generale E Applicatalaw.inventionlawparasitic diseasesmedicineAnimalsHumansLeishmania infantumLeishmania blood donors asympthomatic infectionPolymerase chain reactionbiologyPublic Health Environmental and Occupational HealthGeneral MedicineLeishmania chagasiDNA ProtozoanMiddle Agedmedicine.diseasebiology.organism_classificationLeishmaniaInfectious DiseasesVisceral leishmaniasisItalyImmunologyCarrier Statebiology.proteinLeishmaniasis VisceralParasitologyFemaleAntibodyLeishmania infantumTransactions of the Royal Society of Tropical Medicine and Hygiene
researchProduct

The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing

2004

Budesonide/formoterol in a single inhaler is an effective therapy for asthma. We investigated whether adjustable maintenance dosing with budesonide/formoterol could maintain health-related quality of life (HRQL) and asthma control.Asthma patients (n = 4025) received budesonide/formoterol (Symbicort 160/4.5 microg) 2 inhalations twice daily (b.i.d.) for 4 weeks during run-in of this open, multicentre study. Patients were randomised to adjustable dosing (budesonide/formoterol 1 inhalation b.i.d.; stepping up to 2 or 4 inhalations bid for 1 week if asthma worsened) or fixed dosing (budesonide/formoterol 2 inhalations b.i.d.), for 12 weeks. Change in HRQL (standardised Asthma Quality of Life Qu…

AdultMaleBudesonideAdolescentDrug Administration Scheduleimmune system diseasesFormoterol FumarateAdministration InhalationmedicineHumansAnti-Asthmatic AgentsMetered Dose InhalersDosingBudesonideAgedAsthmaInhalationbusiness.industryInhalerGeneral MedicineMiddle Agedmedicine.diseaseAsthmaRespiratory Function Testsrespiratory tract diseasesDrug CombinationsTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaQuality of LifeFemaleFormoterol FumarateFormoterolbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

2012

SummaryBackgroundStudies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics.MethodsEuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort ® Turbuhaler®)hhNeither the Symbicort SMART posology nor the dry powder formulation, Turbuhaler, is currently approved in the US. maintenance and reliever therapy (Symbicort SMART®) at two maintenance doses of budesonide/formoterol (160/4.5 μg), 1 × 2 and 2 × 2, in patients with asthma who were symptomatic despite treatment with ICS ± long-acting β2-agonists. The 8424 randomised patients included 886 smokers (11%; aged <40 years or with a sm…

AdultMaleBudesonidePulmonary and Respiratory MedicineSymbicort SMARTmedicine.medical_specialtyPeak Expiratory Flow RatePropensity-matched controlsDrug Administration Schedulelaw.inventionACQ-5Budesonide/formoterol maintenance and reliever therapyPharmacotherapyRandomized controlled triallawFormoterol FumarateSurveys and QuestionnairesInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsDosingBudesonideAsthmaSmokersDose-Response Relationship Drugbusiness.industrySmokingmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDisease ProgressionDrug Therapy CombinationFemaleFormoterol FumarateFormoterolbusinessmedicine.drugRespiratory Medicine
researchProduct

Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Ve…

2019

&lt;b&gt;&lt;i&gt;Background/Aims:&lt;/i&gt;&lt;/b&gt; Cardiovascular risk factors are not considered in the current scores for evaluation of the thrombotic risk in myeloproliferative neoplasms, and in polycythemia vera (PV) in particular. Cytoreduction is currently not indicated in low-risk patients with PV, despite the absence or presence of cardiovascular risk factors. Our purpose is to highlight how cardiovascular risk factors in patients with PV increase the thrombotic risk both in low- and high-risk patients. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; We collected and analyzed data from 165 consecutive patients with a diagnosis of PV followed at our institution and compared the fr…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulationCardiovascular risk factorsKaplan-Meier EstimateSettore MED/15 - Malattie Del SangueCytoreductionYoung AdultPolycythemia veraSurvival dataInternal medicinemedicineHumansIn patienteducationAgedRetrospective StudiesAged 80 and overThrombotic riskeducation.field_of_studybusiness.industryThrombosisCytoreduction Surgical ProceduresHematologyMiddle AgedCardiovascular riskmedicine.diseaseThrombosisPolycythemia veraOncologyCardiovascular DiseasesHeart Disease Risk FactorsRisk stratificationFemalebusinessOncology Research and Treatment
researchProduct

A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.

2012

Abstract Background EMD 521873 (Selectikine), an immunocytokine comprising a DNA-targeting antibody, aimed at tumour necrosis, fused with a genetically modified interleukin-2 (IL-2) moiety, was investigated in this first-in-human phase I study. Methods Patients had metastatic or locally advanced solid tumours failing previous standard therapy. Selectikine was administered as a 1-hour intravenous infusion on 3 consecutive days, every 3weeks. A subgroup of patients also received 300mg/m 2 cyclophosphamide on day 1 of each cycle. Escalating doses of Selectikine were investigated with the primary objective of determining the maximum tolerated dose (MTD). Results Thirty-nine patients were treate…

AdultMaleCancer Researchmedicine.medical_specialtyNecrosisCyclophosphamideMaximum Tolerated DoseLymphocyteRecombinant Fusion ProteinsSelectikineAntineoplastic AgentsPharmacologyGastroenterologyEMD 521873Young AdultPhase IDose-escalationInternal medicineNeoplasmsmedicineHumansAgedbiologyDose-Response Relationship Drugbusiness.industryEosinophilMiddle AgedRashAdvanced solid tumoursmedicine.anatomical_structureOncologyToxicitybiology.proteinInterleukin-2SelectikineFemalemedicine.symptomAntibodybusinessmedicine.drugEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Salivary flow and xerostomia in patients with type 2 diabetes

2018

Background: Saliva is secreted by the major and minor salivary glands. There are a number of physiological factors that can reduce this secretion such as age, sex, body weight, number of teeth present in the mouth or time of day. This decrease may also be caused by the use of certain drugs, radiotherapy for head and neck cancer, chronic rheumatic diseases such as Sjögren's syndrome and other systemic disorders such as diabetes mellitus (DM). Objective of this study was to investigate the effect of type 2 DM on salivary secretion and its relation to the sensation of xerostomia. Methods: Forty-seven patients with type 2 DM and 46 healthy individuals, aged 40-80, participated in the study. Sam…

AdultMaleCancer Researchmedicine.medical_specialtySalivadiabetes mellitus type 2saliva xerostomia diabetes mellitus type 22734030209 endocrinology & metabolismStimulationType 2 diabetesSalivary GlandsPathology and Forensic MedicineNO03 medical and health sciencessymbols.namesake0302 clinical medicinestomatognathic systemSurveys and QuestionnairesInternal medicineDiabetes mellitusSensationmedicineHumansxerostomiaFisher's exact testAgedAged 80 and overMealsalivabusiness.industryOtorhinolaryngology2734 Pathology and Forensic MedicineHead and neck cancerMED/28 - MALATTIE ODONTOSTOMATOLOGICHE030206 dentistryMiddle Agedmedicine.diseasestomatognathic diseasesDiabetes Mellitus Type 2OtorhinolaryngologysymbolsPeriodonticsFemaleOral Surgerybusiness
researchProduct

Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Ita…

2011

Invasive local procedures are often reported in clinical history of patients suffering from Bisphosphonates-Related Osteonecrosis of the Jaws (BRONJ) but over 40% of spontaneous forms have been also described in literature. We compared age, gender, underlying bone disorders, bisphosphonate therapy, clinical features and surgical outcome of 205 cases (36.2%) of BRONJ non surgery-triggered (group 1) with 362 (63.8%) cases of surgery-triggered forms (group 2). Differences between group 1 and 2 were analysed using Mann-Whitney U and χ2 tests. Statistical analysis was performed using STATA 8. Zoledronate was the most used type of bisphosphonate (63.4% versus 69.0%) and the mandible was the most …

AdultMaleCancer Researchmedicine.medical_specialtyTooth extractionmedicine.medical_treatmentZoledronic AcidSettore MED/28 - Malattie OdontostomatologicheRisk FactorsClinical historySpontaneous formmedicineRetrospective analysisHumansStatistical analysisStage (cooking)AgedRetrospective StudiesAged 80 and overSurgical outcomeBone Density Conservation AgentsDiphosphonatesBRONJOrthognathic Surgical Proceduresbusiness.industryImidazolesOsteonecrosisBisphosphonates-related Osteonecrosis of the JawMiddle AgedBisphosphonateSurgeryZoledronic acidItalyOncologyMulticenter studyFemaleBisphosphonate therapyOral SurgerybusinessJaw Diseasesmedicine.drugOral Oncology
researchProduct

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

2014

Purpose Advanced systemic mastocytosis (SM), a fatal hematopoietic malignancy characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic hematopoietic stem-cell transplantation (alloHCT) in SM remains unknown. Patients and Methods In a global effort to define the value of HCT in SM, 57 patients with the following subtypes of SM were evaluated: SM associated with clonal hematologic non–mast cell disorders (SM-AHNMD; n = 38), mast cell leukemia (MCL; n = 12), and aggressive SM (ASM; n = 7). Median age of patients was 46 years (range, 11 to 67 years). Donors were HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1)…

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentMedizinDrug resistanceHematopoietic stem cell transplantationMastocytosis SystemicInternal medicinemedicineHumansTransplantation HomologousSystemic mastocytosisChildSurvival rateAgedRetrospective StudiesmastocytosisHematologybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationORIGINAL REPORTSMiddle Agedmedicine.diseaseMast cell leukemia3. Good healthSurvival RateTransplantationSettore MED/15 - MALATTIE DEL SANGUEHaematopoiesisTreatment OutcomeOncologyImmunologyCancer researchFemalebusinesstransplantation
researchProduct